

Product Datasheet

HBsAg Antibody - BSA Free NB100-62652

Unit Size: 0.5 ml

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Publications: 32

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NB100-62652

Updated 9/9/2025 v.20.1

**Earn rewards for product
reviews and publications.**

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NB100-62652



NB100-62652

HBsAg Antibody - BSA Free

Product Information	
Unit Size	0.5 ml
Concentration	4.0 mg/ml
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.1% Sodium Azide
Isotype	IgG
Purity	Protein A purified
Buffer	PBS


Product Description	
Description	Novus Biologicals Rabbit HBsAg Antibody - BSA Free (NB100-62652) is a polyclonal antibody validated for use in IHC, WB, ELISA and ICC/IF. Anti-HBsAg Antibody: Cited in 26 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Rabbit
Gene ID	944569
Gene Symbol	S
Species	Viral
Specificity/Sensitivity	This product is specific for Hepatitis B surface antigen, recognizing subtypes ad and ay. Hepatitis B virus is a major causative agent of acute and chronic liver disease in humans. Hepatitis B surface antigen (HBsAg) is a protein component of the viral envelope, which is expressed predominantly in the cytoplasm of infected hepatocytes.
Immunogen	Hepatitis B subtypes ad and ay

Product Application Details	
Applications	Western Blot, Immunohistochemistry-Paraffin, ELISA, Immunohistochemistry, Immunohistochemistry-Frozen
Recommended Dilutions	Western Blot 1:1000-1:3000, ELISA 1:10000, Immunohistochemistry 1:10-1:500, Immunohistochemistry-Paraffin 1:10-1:500, Immunohistochemistry-Frozen




Images

Western Blot: HBsAg Antibody [NB100-62652] - HepAD38 cells were treated with DFMO (50 μ M, 100 μ M), and the HBV core-associated DNA was extracted 3 days later and measured by Southern blot (upper panel). The levels of HBc and HBs were measured by Western blotting, and capsids levels were determined using a Native gel assay (lower panel). Image collected and cropped by CiteAb from the following publication (frontiersin.org/article/10.3389/fcimb.2020.00158/full), licensed under a CC-BY license.



Western Blot: HBsAg Antibody [NB100-62652] - DFMO decreases the HBV core-associated DNA & the HBc protein levels. (A) Determination of cytotoxicity of HepAD38 & HepG2.2.15 cells treated DFMO measured by the MTS assay. (B) HepAD38 cells were treated with DFMO (50 μ M, 100 μ M), & the HBV core-associated DNA was extracted 3 days later & measured by Southern blot (upper panel). The levels of HBc & HBs were measured by Western blotting, & capsids levels were determined using a Native gel assay (lower panel) as described above. (C) The levels of HBsAg in supernatant were measured by ELISA assay as described above. (D) HBV 3.5kb RNA levels were measured by real-time RT-PCR. (E) & (F) HepG2.2.15 cells treated with DFMO (50, 100 μ M) for 3 days, then the levels of intracellular HBV DNA or HBsAg levels in the supernatant were detected by real-time PCR (E) or ELISA assay (F). (G) DFMO decreased the infection capacity of the HBV particles. HepAD38 cells in the absence of tetracycline were treated with DSMO or DFMO with indicated concentration for 3 days, & the HBV viral particles were then collected & added to the HepG2-NTCP cells. Five days later, the cytoplasmic viral DNA were extracted & measured by real-time PCR. RC, relaxed circular; DL, double stranded linear; SS, single stranded. Experiments were performed in triplicate, & data are represented as means \pm SD. Statistical significance was determined by one-way ANOVA with the Tukey post-hoc test (* $p < 0.05$; ns, not significant). Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/32373551>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Pantazica A, Hammel A, Caras I et al. Red Alga *Porphyridium* Supports High-Yield Production of a Functional Chimeric Hepatitis B Surface Antigen With Strong Cellular and Humoral Immunogenicity. *Plant biotechnology journal* 2025-07-22 [PMID: 40693441]

Zhao W, Singh K, Sozzi V et al. Hepatitis B surface antigen is upregulated by HIV Tat in an HIV–hepatitis B virus co-infection model system *Microbiology Spectrum* 2025-09-01 [PMID: 40698826]

Mao B, Wang Z, Pi S et al. Difluoromethylornithine, a Decarboxylase 1 Inhibitor, Suppresses Hepatitis B Virus Replication by Reducing HBc Protein Levels *Frontiers in Cellular and Infection Microbiology* 2020-04-16 [PMID: 32373551]

Shen Z, Yang H, Yang S et al. Hepatitis B virus persistence in mice reveals IL-21 and IL-33 as regulators of viral clearance *Nature Communications* 2017-12-14 [PMID: 29242561]

Qin YP, Yu HB, Yuan SY et al. KAT2A Promotes Hepatitis B Virus Transcription and Replication Through Epigenetic Regulation of cccDNA Minichromosome *Frontiers in Microbiology* 2022-01-24 [PMID: 35140694]

Xie H, Xie D, Zhang J et al. ROS/NF- κ B Signaling Pathway-Mediated Transcriptional Activation of TRIM37 Promotes HBV-Associated Hepatic Fibrosis *Molecular Therapy - Nucleic Acids* 2020-12-01 [PMID: 32916597]

Jeong GU, Ahn BY, Jung J et al. A recombinant human immunoglobulin with coherent avidity to hepatitis B virus surface antigens of various viral genotypes and clinical mutants *PLOS ONE* 2020-08-13 [PMID: 32790777]

Dewinter J, Onaiwu MG, Massolo ML et Al. Short report: Recommendations for education, clinical practice, research, and policy on promoting well-being in autistic youth and adults through a positive focus on sexuality and gender diversity *Autism* 2023-08-02 [PMID: 37530121]

Li R, Wang C, Xu K et al. Asiatic acid inhibits HBV cccDNA transcription by promoting HBx degradation *Virology Journal* 2024-10-28 [PMID: 39468627]

Ye Y, Fu Y, Lin C et al. Oncostatin M induces IFITM1 expression to inhibit hepatitis B virus replication via JAK-STAT signaling *Cellular and molecular gastroenterology and hepatology* 2023-10-23 [PMID: 37879404]

Zheng Y, Yang L, Yu L et al. Canocapavir Is a Novel Capsid Assembly Modulator Inducing a Conformational Change of the Linker Region of HBV Core Protein *Viruses* 2023-05-18 [PMID: 37243280] (WB)

Yi J, Lei X, Guo F et al. Codelivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models *Antiviral Research* 2023-05-01 [PMID: 37142191] (WB, Mouse, Tree Shrew)

More publications at <http://www.novusbio.com/NB100-62652>





Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NB100-62652

NBP2-33376H	Blue Marker Antibody (6F4-F6) [HRP]
HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NB100-62652

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

